Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials

J Antimicrob Chemother. 2007 Dec;60(6):1411-3. doi: 10.1093/jac/dkm367. Epub 2007 Oct 2.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Darunavir
  • Drug Resistance, Viral / genetics
  • Drug Therapy, Combination
  • Genotype
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV Protease Inhibitors* / administration & dosage
  • HIV Protease Inhibitors* / therapeutic use
  • HIV Protease* / drug effects
  • HIV Protease* / genetics
  • HIV Protease* / metabolism
  • HIV-1 / drug effects*
  • HIV-1 / enzymology
  • HIV-1 / genetics
  • Humans
  • Microbial Sensitivity Tests
  • Mutation
  • Phenotype
  • RNA, Viral / blood
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Ritonavir / administration & dosage
  • Ritonavir / therapeutic use
  • Sulfonamides* / administration & dosage
  • Sulfonamides* / therapeutic use
  • Treatment Outcome
  • Viral Load

Substances

  • HIV Protease Inhibitors
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Sulfonamides
  • HIV Protease
  • Ritonavir
  • Darunavir